Viva Biotech executives detail cyclic peptide manufacturing bottlenecks
Company says a 5°C shift during solid-phase synthesis can triple impurities, and 30-residue chains finish at only 30–60% purity before purification.
The wire
- 01In a BioSpace interview, Viva Biotech's Susan Chen and Yue Qian described solid-phase peptide synthesis limits: 30-plus steps for a 30-amino-acid chain, 30–60% crude purity, and 2,000–5,000 litre reactors costing tens of millions.
- 02Manufacturing capacity and reproducibility shape supply and cost for every peptide drug, including GLP-1 analogues and the cyclic peptides now entering development.
- 03Viva says its hybrid solid- and liquid-phase approach reached kilogram scale at 99% or higher purity for GLP-1 analogues; the claims are the company's own and were not independently verified.
From the source
Read at biospace.comCyclic peptides open new drug frontiers, if manufacturing can keep up
Peptide therapeutics are an increasingly hot area for drug development, fueled by the explosive GLP-1 obesity market. But peptides can pose scientific and operational challenges, such as low bioavailability and that their production is notoriously sensitive to many factors. These include reactor geometry, resin swelling and even a 5°C operation temperature shift.